CDK4 and breast cancer: More recently, in the treatment of metastatic breast cancer, selective small molecule CDK4/6 inhibitors have also become increasingly effective, such as palbociclib, ribociclib and abemaciclib, which have been developed in metastatic luminal breast cancer (Cadoo et al., 2014).